MedPath

Evaluation of the Clinical Efficacy and Safety of BriTurn Injection or BrisTurn Prefilled Injection

Recruiting
Conditions
Reversal of Neuromuscular Blockade
Registration Number
NCT06246331
Lead Sponsor
Hanlim Pharm. Co., Ltd.
Brief Summary

This study evaluate clinical efficacy and safety in adult patients administered BriTurn injection or BrisTurn Prefilled injection for reversal of neuromuscular blockade induced by Rocuronium or Vecuronium.

Detailed Description

This study evaluate clinical efficacy and safety in adult patients administered BriTurn injection or BrisTurn Prefilled injection for reversal of neuromuscular blockade induced by Rocuronium or Vecuronium.

* Efficacy: Time (minutes) for Train-Of-Four (TOF) ratio to reach 0.9 (90%)

* Safety: whether bradycardia and resulting cardiac arrest occur or whether bronchospasm occurs

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
1500
Inclusion Criteria
  • Adults over 19 years of age
  • Subject administered BriTurn Injection or BrisTurn Prefilled Injection for reversal of neuromuscular blockade induced by Rocuronium or Vecuronium
Exclusion Criteria
  • Pregnant women or nursing women
  • Subject to prohibition according to the permission of BriTurn Injection or BrisTurn Prefilled Injection

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Time (minutes) for Train-Of-Four (TOF) ratio to reach 0.9 (90%)after administration of BriTurn Injection or BrisTurn Prefilled Injection up to 3 minutes

Time (minutes) for Train-Of-Four (TOF) ratio to reach 0.9 (90%) after administration of BriTurn Injection or BrisTurn Prefilled Injection up to 3 minutes

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Inje University Sanggye Paik Hospital

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath